[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
The World in Medicine
September 9, 1998

No Survival Advantage

Author Affiliations

Not Available

Not Available

JAMA. 1998;280(10):873. doi:10.1001/jama.280.10.873

High-dose chemotherapy accompanied by infusions of blood stem cells apparently offers no survival advantage over standard chemotherapy for women with breast cancer.

A study by researchers at the Netherlands Cancer Institute in Amsterdam included 97 women with breast cancer that had spread to the lymph nodes. After three courses of chemotherapy and surgery, 81 women whose tumors responded to therapy by shrinking or not growing larger were randomized to receive a fourth course of standard chemotherapy or a high-dose regimen and blood stem cells.

First Page Preview View Large
First page PDF preview
First page PDF preview